^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CYSLTR2 L129Q

    i
    Other names: Cysteinyl Leukotriene Receptor 2, CYSLT2R, G-Protein Coupled Receptor GPCR21, G-Protein Coupled Receptor HG57, HGPCR21, CYSLT2, HPN321, Cysteinyl Leukotriene CysLT2 Receptor, PSEC0146, CysLT(2), KPG_011, CYSLTR2, CysLTR2, GPCR21, HG57
    Entrez ID:
    57105
    over2years
    Attempting to Solve the Pigmented Epithelioid Melanocytoma (PEM) Conundrum: PRKAR1A Inactivation Can Occur in Different Genetic Backgrounds (Common, Blue, and Spitz Subgroups) With Variation in Their Clinicopathologic Characteristics. (PubMed, Am J Surg Pathol)
    These results could potentially shift the concept of PRKAR1A-inactivated melanocytoma, changing from a rather unified model to a more complex one, including genetic subgroup variations with clinical and morphologic specificities. The genetic background of PRKAR1A-inactivated melanocytic tumors should be systematically explored to better understand the extent and clinical behavior of these complex lesions.
    Journal
    |
    BRAF (B-raf proto-oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • GNAQ (G Protein Subunit Alpha Q) • CYSLTR2 (Cysteinyl Leukotriene Receptor 2) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha) • PRKCA (Protein Kinase C Alpha)
    |
    BRAF V600E • BRAF V600 • GNAQ Q209L • HRAS mutation • CYSLTR2 L129Q • PRKCA mutation